Placebo News and Research

RSS

Recreational drug may help people regain trust in others

The recreational drug known as ecstasy or molly may help people regain trust in others after being betrayed, suggests results of a controlled laboratory study, published in JNeurosci, of healthy men given a pure form of the substance.

From Society for Neuroscience 19 Nov 2018

FDA approves antibacterial drug to treat travelers' diarrhea

The U.S. Food and Drug Administration today approved Aemcolo (rifamycin), an antibacterial drug indicated for the treatment of adult patients with travelers' diarrhea caused by noninvasive strains of Escherichia coli (E. coli), not complicated by fever or blood in the stool.

17 Nov 2018

New artificial intelligence-based method predicts treatment effectiveness

How can a doctor predict the treatment outcome of an individual patient? Traditionally, the effectiveness of medical treatments is studied by randomized trials where patients are randomly divided into two groups: one of the groups is given treatment, and the other a placebo.

16 Nov 2018

Angiotensin receptor blockers improve sodium excretion in blacks

Drugs that inhibit a hormone that constricts blood vessels also help improve sodium excretion in blacks who hold onto too much sodium in the face of stress, investigators report.

13 Nov 2018

Fish oil or omega 3 fatty acid supplements can prevent heart attacks finds study

A couple of clinical trials from Harvard researchers have shown that regular consumption of fish or fish oil supplements can reduce the risk of getting heart attacks significantly.

13 Nov 2018

Diabetes medication reduces risk of heart failure hospitalization

In the largest trial to date to assess cardiovascular outcomes for an important class of diabetes medications, researchers have found that dapagliflozin markedly reduced the risk of hospitalization for heart failure in a broad population of patients with diabetes.

12 Nov 2018

Inexpensive and effective drug does not reduce major adverse cardiovascular event rates

When it comes to reducing inflammation to decrease the risk of heart disease and stroke, results from the much-anticipated Cardiovascular Inflammation Reduction Trial indicate that targeting the right inflammatory pathways in at-risk patients is crucial.

12 Nov 2018

Hypertonic saline shown to aid breathing in cystic fibrosis babies

The first-ever randomized controlled trial on babies with CF has found that treatment with inhaled hypertonic saline can improve breathing and lung health.

9 Nov 2018

Targeting one brain region with alternating current could decrease symptoms of chronic pain

For the first time, researchers at the UNC School of Medicine showed they could target one brain region with a weak alternating current of electricity, enhance the naturally occurring brain rhythms of that region, and significantly decrease symptoms associated with chronic lower back pain.

9 Nov 2018

New study does not support hypertensive effect from urate elevation

A study from a group of Massachusetts General Hospital investigators may reduce the concern that elevating levels of urate, an approach being investigated to treat several neurodegenerative disorders, could increase the risk of hypertension.

8 Nov 2018

Exploring why some athletes ice their muscles after exercise

We've all seen it, after a gruelling and physical rugby many athletes plunge themselves into a bath of icy cold water or even in a cold air chamber, a treatment known as cryotherapy.

8 Nov 2018

Cholesterol-lowering drug reduces chance of having second heart problems or stroke

In a clinical trial involving 18,924 patients from 57 countries who had suffered a recent heart attack or threatened heart attack, researchers at the University of Colorado Anschutz Medical Campus and fellow scientists around the world have found that the cholesterol-lowering drug alirocumab reduced the chance of having additional heart problems or stroke.

8 Nov 2018

Cannabinoids hold promise in treating children with epilepsy

In recent years, cannabinoids--the active chemicals in medical marijuana-- have been increasingly touted as a potential treatment for a range of neurological and psychiatric disorders. In a Developmental Medicine & Child Neurology review, investigators compare their efficacy with antiepileptic drugs for children with epilepsy.

7 Nov 2018

New heart drug spotlights troubling trends in drug marketing

At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease.

2 Nov 2018

Drug combination not more effective in improving depression than single antidepressant

Psychiatrists and GPs increasingly combine mirtazapine with an SSRI (selective serotonin reuptake inhibitor) or SNRI (serotonin-noradenaline reuptake inhibitor) antidepressant for patients whose depression does not respond to a single antidepressant.

1 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

Ark Biosciences, a biotech company developing proprietary therapeutics for viral infection and respiratory diseases, announced today the significant progress in its phase 2 proof-of-concept study of ziresovir in the treatment of hospitalized RSV infected infants.

1 Nov 2018

World’s first vaccine against coeliac disease to be tested in Australia

US-based pharmaceutical company ImmusanT, after worldwide trials, is all set to start clinical trials of a new vaccine against coeliac disease at the Royal Melbourne Hospital Clinical Trials Centre in Melbourne. This will be followed by trials to be held at Adelaide, Brisbane, Perth, Mackay and Sunshine Coast say the sources.

31 Oct 2018

Using genome editing to prevent sudden cardiac death

Each year, at least 3 million people worldwide die of sudden cardiac death. In the U.S., this number reaches up to 450,000 people.

30 Oct 2018

PrEP shown to be safe and effective for widespread use

New research presented at the HIV Drug Therapy Conference in Glasgow today shows that pre-exposure prophylaxis could be given to millions of people worldwide with no increased risk of safety issues during treatment.

30 Oct 2018

Placebo News and Research

Recreational drug may help people regain trust in others

FDA approves antibacterial drug to treat travelers' diarrhea

New artificial intelligence-based method predicts treatment effectiveness

Angiotensin receptor blockers improve sodium excretion in blacks

Fish oil or omega 3 fatty acid supplements can prevent heart attacks finds study

Diabetes medication reduces risk of heart failure hospitalization

Inexpensive and effective drug does not reduce major adverse cardiovascular event rates

Hypertonic saline shown to aid breathing in cystic fibrosis babies

Targeting one brain region with alternating current could decrease symptoms of chronic pain

New study does not support hypertensive effect from urate elevation

Exploring why some athletes ice their muscles after exercise

Cholesterol-lowering drug reduces chance of having second heart problems or stroke

Cannabinoids hold promise in treating children with epilepsy

New heart drug spotlights troubling trends in drug marketing

Drug combination not more effective in improving depression than single antidepressant

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Phase 2 study of ziresovir for treating hospitalized RSV infected infants achieves significant progress

World’s first vaccine against coeliac disease to be tested in Australia

Using genome editing to prevent sudden cardiac death

PrEP shown to be safe and effective for widespread use

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News